Communiqués Marinomed Biotech AG Börse Stuttgart

Actions

93Z

ATMARINOMED6

Marché Fermé - Börse Stuttgart Autres places de cotation 15:31:03 25/06/2024			Varia. 5j.	Varia. 1 janv.
12,5 ^EUR	-1,57%		-1,19%	-58,88%

22/05	Transcript : Marinomed Biotech AG, Q1 2024 Earnings Call, May 22, 2024
21/05	Marinomed Biotech AG annonce ses résultats pour le premier trimestre clos le 31 mars 2024	CI

Communiqués

Débloquez toutes les actualités : Soyez le premier informé et réagissez avant les marchés !

Inscription 100% Gratuite

Marinomed Biotech AG secures licensure with leading Consumer Health Care player for the distribution of Carragelose® products in Europe	14/06	EQ
Marinomed Biotech : Remuneration policy for members of the Management Board 2024	29/05	PU
Marinomed Biotech : Remuneration policy for members of the Supervisory Board 2024	29/05	PU
AGM: Marinomed Biotech AG: Invitation to the 7th Annual General Meeting on Thursday, June 20, 2024, at 13:00 (Vienna time)	23/05	EQ
Marinomed Biotech : Update Q1 2024	22/05	PU
Marinomed Biotech AG announces results for the first quarter of 2024	22/05	EQ
Marinomed Biotech AG enters Solv4U R&D collaboration with Brazilian pharmaceutical company Aché Laboratórios	25/04	EQ
AFR: Marinomed Biotech AG: Release of a Financial report	16/04	EQ
Marinomed Biotech AG announces results for the 2023 financial year and reports progress with Marinosolv and Carragelose assets	16/04	EQ
AFR: Marinomed Biotech AG: Release of a Financial report	16/04	EQ
Marinomed Biotech AG: Release according to Article 135, Section 2 BörseG with the objective of Europe-wide distribution	15/04	EQ
Marinomed Biotech AG: Launch of new allergen-blocking Carragelose product in Austria and market entry in Mexico	11/04	EQ
Marinomed Biotech AG announces agreement with European Investment Bank (EIB) to defer repayments of the 2019 venture loan for 18 months	28/03	EQ
Marinomed Biotech AG enters new Carragelose distribution partnerships for Gulf region and Eastern Europe	26/03	EQ
Marinomed Biotech AG: Lucia Ziegler new Head of Investor & Public Relations	01/03	EQ
Marinomed Biotech AG announces preliminary revenue for 2023	14/02	EQ
Marinomed Biotech AG with important progress for Carragelose in 2024	07/02	EQ
Marinomed Biotech AG evaluates strategic options for Carragelose portfolio	18/12	EQ
Marinomed Biotech AG evaluates strategic options for Carragelose portfolio	18/12	EQ
Marinomed Biotech AG with new Carragelose distribution and manufacturing partners and EU patent	14/12	EQ

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Communiqués Marinomed Biotech AG Börse Stuttgart

Actions

93Z

ATMARINOMED6

Communiqués

Filtres